This educational supplement discusses updated treatment guidelines for bacterial vaginosis (BV) and reviews literature on the association of BV and the risk of sexually transmitted infections that supports the need for proper BV treatment, whether symptomatic or asymptomatic.
Download the supplement
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
Trends in STI prevalence and testing guidelines
April 11th 2024In a recent interview, Cheruba Prabakar, MD, FACOG, shed light on the rising prevalence of sexually transmitted infections in the United States and the need for improved awareness and testing, particularly for overlooked conditions such as trichomoniasis.
Read More
NIH study finds long-acting ART safe for HIV suppression in adolescents
March 7th 2024Research presented at the 2024 Conference on Retroviruses and Opportunistic Infections reveals that long-acting injectable antiretroviral therapy provides improved HIV suppression with minimal adverse effects, offering a promising alternative for adolescents and individuals struggling with daily oral regimens.
Read More